If I'm not mistaken, the users of this service primarily want to obtain specific prescription medications at a low cost. Then price competition is likely to become an issue quickly. Additionally, the TAM is unlikely to expand. Fields like hair loss, dieting, and sexual health succeed because the treatments have a low dependency on physicians.
Interesting company. Never heard of it. It just became profitable, it's a good sign. Technically, it's almost completed its IPO bottom. Also a good sign, although now that the price is near the all-time high, it'll probably need a bombastic earnings report to go over the high of 2021. The stock-based compensation has led from 192M shares to 214M shares over the last two years. I wouldn't be happy if I held the stock but young IPOs are like that. You have to factor in this risk. Overall, a nice pick, Oliver.
If I'm not mistaken, the users of this service primarily want to obtain specific prescription medications at a low cost. Then price competition is likely to become an issue quickly. Additionally, the TAM is unlikely to expand. Fields like hair loss, dieting, and sexual health succeed because the treatments have a low dependency on physicians.
Interesting company. Never heard of it. It just became profitable, it's a good sign. Technically, it's almost completed its IPO bottom. Also a good sign, although now that the price is near the all-time high, it'll probably need a bombastic earnings report to go over the high of 2021. The stock-based compensation has led from 192M shares to 214M shares over the last two years. I wouldn't be happy if I held the stock but young IPOs are like that. You have to factor in this risk. Overall, a nice pick, Oliver.